date,title,source
Nov-13-18,"AVROBIO, Inc. Reports Third Quarter 2018 Financial Results and Provides Business Update",GlobeNewswire
Nov-21-18,"Analysis: Positioning to Benefit within The ONE Group Hospitality, Biofrontera AG Sponsored ADR, Aridis Pharmaceuticals, Universal Logistics, Tonix Pharmaceuticals Holding, and AVROBIO  Research Highlights Growth, Revenue, and Consolidated Results",GlobeNewswire
Nov-28-18,Leerink Starts Coverage Of Genetic Medicine Stocks: 'We See Commercial Execution As Increasingly Driving Returns',Benzinga
Dec-18-18,"AVROBIO, Inc. Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)",GlobeNewswire
Dec-18-18,"AVROBIO, Inc. Expands and Strengthens Leadership Team with Four Senior Management Hires",GlobeNewswire
Dec-19-18,AVROBIO Receives Orphan-Drug Designation from the U.S. FDA for AVR RD 01 for the Treatment of Fabry Disease,GlobeNewswire
Dec-21-18,"AVROBIO, Inc. Added to NASDAQ Biotechnology Index",GlobeNewswire
Dec-21-18,"Should You Avoid AVROBIO, Inc. (AVRO)?",Insider Monkey
Jan-07-19,"AVROBIO, Inc. Appoints Philip J. Vickers to its Board of Directors",GlobeNewswire
Jan-17-19,"AVROBIO, Inc. Announces Analyst and Investor Event and Upcoming Clinical Data Presentations at WORLDSymposium 2019",GlobeNewswire
Jan-18-19,AVROBIO Enters Oversold Territory,Zacks
Jan-18-19,"AVROBIO, Inc. Announces Acceptance of Investigational New Drug (IND) Application for Investigator-Sponsored Phase 1/2 Clinical Trial for AVR-RD-04 Gene Therapy for Cystinosis",GlobeNewswire
Feb-01-19,"AVROBIO, Inc. Announces Time Change for Analyst and Investor Presentation and Webcast, now 5:30 p.m. ET on Wednesday, February 6, 2019",GlobeNewswire
Feb-05-19,"Investors Are Undervaluing AVROBIO, Inc. (NASDAQ:AVRO) By 46.82%",Simply Wall St.
Mar-05-19,"AVROBIO, Inc. to Present at the Cowen and Company 39th Annual Health Care Conference",Business Wire
Mar-25-19,"AVROBIO, Inc. Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Provides Business Update",Business Wire
Apr-26-19,AVROBIO Highlights the plato Platform and Gaucher and Cystinosis Programs at the 2019 Annual Meeting of the American Society of Gene and Cell Therapy,Business Wire
Apr-29-19,"AVROBIO, Inc. Announces FDA Clearance of Investigational New Drug Application for AVR-RD-01 Gene Therapy for the Treatment of Fabry Disease",Business Wire
May-13-19,"AVROBIO, Inc. Reports First Quarter 2019 Financial Results and Provides Business Update",Business Wire
